Follow
Associate Professor Veysel Kayser
Associate Professor Veysel Kayser
School of Pharmacy, The University of Sydney
Verified email at sydney.edu.au - Homepage
Title
Cited by
Cited by
Year
Design of therapeutic proteins with enhanced stability
N Chennamsetty, V Voynov, V Kayser, B Helk, BL Trout
Proceedings of the National Academy of Sciences 106 (29), 11937-11942, 2009
6202009
The state-of-play and future of antibody therapeutics
Z Elgundi, M Reslan, E Cruz, V Sifniotis, V Kayser
Advanced drug delivery reviews 122, 2-19, 2017
3202017
Prediction of aggregation prone regions of therapeutic proteins
N Chennamsetty, V Voynov, V Kayser, B Helk, BL Trout
The Journal of Physical Chemistry B 114 (19), 6614-6624, 2010
1992010
Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy
E Cruz, V Kayser
Biologics: targets and therapy, 33-51, 2019
1872019
Aggregation-prone motifs in human immunoglobulin G
N Chennamsetty, B Helk, V Voynov, V Kayser, BL Trout
Journal of molecular biology 391 (2), 404-413, 2009
1802009
Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies
V Kayser, N Chennamsetty, V Voynov, K Forrer, B Helk, BL Trout
Biotechnology journal 6 (1), 38-44, 2011
1732011
Ionic liquids as biocompatible stabilizers of proteins
M Reslan, V Kayser
Biophysical reviews 10, 781-793, 2018
1062018
Evaluation of a non-Arrhenius model for therapeutic monoclonal antibody aggregation
V Kayser, N Chennamsetty, V Voynov, B Helk, K Forrer, BL Trout
Journal of pharmaceutical sciences 100 (7), 2526-2542, 2011
1022011
Femtosecond electron-transfer reactions in mono-and polynucleotides and in DNA
GD Reid, DJ Whittaker, MA Day, DA Turton, V Kayser, JM Kelly, ...
Journal of the American Chemical Society 124 (19), 5518-5527, 2002
952002
Advances and limitations of antibody drug conjugates for cancer
CM Mckertish, V Kayser
Biomedicines 9 (8), 872, 2021
712021
An overview of influenza viruses and vaccines
RF Nuwarda, AA Alharbi, V Kayser
Vaccines 9 (9), 1032, 2021
702021
Predictive tools for stabilization of therapeutic proteins
V Voynov, N Chennamsetty, V Kayser, B Helk, BL Trout
MAbs 1 (6), 580-582, 2009
702009
Vaccines and vaccination: history and emerging issues
V Kayser, I Ramzan
Human vaccines & immunotherapeutics 17 (12), 5255-5268, 2021
692021
Current advancements in addressing key challenges of therapeutic antibody design, manufacture, and formulation
V Sifniotis, E Cruz, B Eroglu, V Kayser
Antibodies 8 (2), 36, 2019
672019
New compounds based on a benzimidazole nucleus: synthesis, characterization and cytotoxic activity against breast and colon cancer cell lines
S Akkoç, V Kayser, İÖ İlhan, DE Hibbs, Y Gök, PA Williams, B Hawkins, ...
Journal of Organometallic Chemistry 839, 98-107, 2017
672017
Vaccine hesitancy: contemporary issues and historical background
RF Nuwarda, I Ramzan, L Weekes, V Kayser
Vaccines 10 (10), 1595, 2022
622022
Poly (methyl vinyl ether-co-maleic acid)–Pectin based hydrogel-forming systems: Gel, film, and microneedles
YK Demir, AÜ Metin, B Şatıroğlu, ME Solmaz, V Kayser, K Mäder
European Journal of Pharmaceutics and Biopharmaceutics 117, 182-194, 2017
622017
Design and application of antibody cysteine variants
V Voynov, N Chennamsetty, V Kayser, HJ Wallny, B Helk, BL Trout
Bioconjugate chemistry 21 (2), 385-392, 2010
592010
A narrative review of COVID-19 vaccines
B Eroglu, RF Nuwarda, I Ramzan, V Kayser
Vaccines 10 (1), 62, 2021
572021
Dynamic fluctuations of protein-carbohydrate interactions promote protein aggregation
V Voynov, N Chennamsetty, V Kayser, B Helk, K Forrer, H Zhang, ...
PLoS One 4 (12), e8425, 2009
562009
The system can't perform the operation now. Try again later.
Articles 1–20